Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market open
8 134,15 pts
-0.16%


Last updated : 19/11/2026 - 15h46
🏠 Home   ➤    Stock news

Valneva shares rebound but are down 15.5% over three months

The Lyon-based vaccine company is recovering markedly at midday, while the Paris stock market is posting a modest gain. This rebound follows several sessions of decline and comes a few days before the publication of its accounts.


Valneva shares rebound but are down 15.5% over three months

A rebound that leaves the stock below its moving averages

Valneva shares gain 2.43% to €2.49 during the session, ranking among the strongest gains in its index, while the SBF 120 rises 0.35%. The stock nonetheless remains 1.15% below its MM20 (€2.52), and both the MM50 and the MM200 are also above the share price.

The move recovers only part of the week's decline, which reaches 6.95% over seven days, following a Wednesday session spent in the bottom of the index. The RSI at 47 remains neutral. The support at €2.33 is the nearest downside level, while the resistance at €2.68 is the nearest upside level.

Results for the first nine months expected on November 24

Valneva will publish its results for the first nine months of 2026 on November 24. When it published its H1 2026 results on August 13, the company confirmed its outlook for the year despite the persistent negative impact of the geopolitical context on travel.

Among the risks cited on that occasion was the company's dependence on IXIARO deliveries to the U.S. Department of Defense, whose timing remains uncertain.

On the clinical front, the group released new data in early November on its chikungunya vaccine, with a seroresponse maintained at 94% five years after a single dose. Over three months, the stock has fallen 15.47%. The November 24 publication is the company's next scheduled event.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Pharmacie, vaccins et santé animale


Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 65,8 millions d'euros
  • Quarterly revenue: 65,8 millions d'euros
  • Revenue growth: -32,6 %
  • EBITDA: -39,8 millions d'euros
  • EBITDA margin: -60,4 %
  • Net income: -63,3 millions d'euros
Guidance from the release
  • Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
  • Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
  • Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
  • Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
  • Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
  • Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
  • Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
  • Expected revenue: 147,5 millions d'euros

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours